Saskatchewan Immunization Manual Amendments 2021-11-22

Instructions: Please remove and discard the corresponding pages in each chapter section as applicable and insert the amended pages as noted below in each corresponding chapter section.

Chapter 10 Biological Products

- TOC
  - Pfizer BioNTech Comirnaty 5-11 years added to TOC

- AstraZeneca COVISHIELD COVID-19 vaccine
  - New information under dose and scheduling row:

    Primary series for non-immune compromised individuals
    - 2 doses of 0.5 ml
      - Dose 1: day 0
      - Dose 2: **8 weeks** is the recommended interval between the first and second doses (minimum interval of 28 days).
      - NOTE: mRNA vaccine **is preferred** as the second dose for those who received AZ or COVISHIELD as their first dose (unless contraindicated), resulting in increased immunogenicity.
      - It is recommend that people who received two doses of AZ and/or COVISHIELD as a primary series receive an mRNA booster vaccine at 6 months after completion of their primary series. A viral vector vaccine could be given to those for whom there is a contraindication to an mRNA vaccine.

    Primary series for moderately to severe immune compromised individuals
    - 3 doses of 0.5 ml
      - Dose 1: day 0
      - Dose 2: min. 28 days later
      - Dose 3: min. 28 days later
      - For those who are moderately to severely immunocompromised in the authorized age group who have not yet been immunized, a primary series of three doses of an authorized mRNA vaccine should be offered. For those who are moderately to severely immunocompromised in the authorized age group who have previously received a 1- or 2-dose COVID-19 vaccine series (with a homologous or heterologous schedule using mRNA or viral vector vaccines), an additional dose of an authorized mRNA COVID-19 vaccine should be offered (NACI, 2021).
  - Addition to Anaphylaxis under contraindication row: NOTE: In individuals with a confirmed severe, immediate (≤4h following exposure) allergy (e.g., anaphylaxis) to a component of a specific COVID-19 vaccine, a consultation with an allergist is recommended before receiving the specific COVID-19 vaccine.

- Janssen (Johnson & Johnson) COVID-19 vaccine
  - New addition under schedule:
    - 1-dose primary series;
    - It is recommended that an mRNA booster vaccine be given at least 2 months after the primary dose of Janssen was received, if only a single dose has been received.
  - Addition to Anaphylaxis under contraindication row: NOTE: In individuals with a confirmed severe, immediate (≤4h following exposure) allergy (e.g., anaphylaxis) to a component of a specific COVID-19 vaccine, a consultation with an allergist is recommended before receiving the specific COVID-19 vaccine.

Saskatchewan Immunization Manual Amendments 2021-11-22

- Moderna COVID-19 vaccine
  - New information under dose and scheduling row:
    Primary series for non-immune compromised individuals
    - 2 doses of 0.5 ml
      - Dose 1: day 0
      - Dose 2: **8 weeks** is the recommended interval between the first and second doses (minimum interval of 28 days).
      - NOTE: mRNA vaccine **is preferred** as the second dose for those who received AZ or COVISHIELD as their first dose (unless contraindicated), resulting in increased immunogenicity.
      - It is recommend that people who received two doses of AZ and/or COVISHIELD as a primary series receive an mRNA booster vaccine at 6 months after completion of their primary series. A viral vector vaccine could be given to those for whom there is a contraindication to an mRNA vaccine.

    Primary series for moderately to severe immune compromised individuals
    - 3 doses of 0.5 ml
      - Dose 1: day 0
      - Dose 2: min. 28 days later
      - Dose 3: min. 28 days later
      - For those who are moderately to severely immunocompromised in the authorized age group who have not yet been immunized, a primary series of three doses of an authorized mRNA vaccine should be offered. For those who are moderately to severely immunocompromised in the authorized age group who have previously received a 1- or 2-dose COVID-19 vaccine series (with a homologous or heterologous schedule using mRNA or viral vector vaccines), an additional dose of an authorized mRNA COVID-19 vaccine should be offered (NACI, 2021).
  - Addition to Anaphylaxis under contraindication row: NOTE: In individuals with a history of a severe, immediate (≤4h following vaccination) allergic reaction (e.g., anaphylaxis) after previous administration of an mRNA COVID-19 vaccine, re-vaccination (i.e. administration of a subsequent dose in the series when indicated) may be offered with the same vaccine or the same mRNA platform if a risk assessment deems that the benefits outweigh the potential risks for the individual and if informed consent is provided.

- Pfizer +12 years COVID-19 vaccine (Purple cap)
  - Statement removed: Children born in 2009 are eligible for immunization with this vaccine until a pediatric (5-11 years) formulation is licensed.
  - New information under dose and scheduling row:
    Primary series for non-immune compromised individuals
    - 2 doses of 0.3 ml
      - Dose 1: day 0
      - Dose 2: **8 weeks** is the recommended interval between the first and second doses (minimum interval of 28 days).
      - NOTE: mRNA vaccine **is preferred** as the second dose for those who received AZ or COVISHIELD as their first dose (unless contraindicated), resulting in increased immunogenicity.
      - It is recommend that people who received two doses of AZ and/or COVISHIELD as a primary series receive an mRNA booster vaccine at 6 months after completion of their primary series. A viral vector vaccine could be given to those for whom there is a contraindication to an mRNA vaccine.

Saskatchewan Immunization Manual Amendments 2021-11-22

Primary series for moderately to severe immune compromised individuals

- 3 doses of 0.3 ml
  - Dose 1: day 0
  - Dose 2: min. 28 days later
  - Dose 3: min. 28 days later
  - For those who are moderately to severely immunocompromised in the authorized age group who have not yet been immunized, a primary series of three doses of an authorized mRNA vaccine should be offered. For those who are moderately to severely immunocompromised in the authorized age group who have previously received a 1- or 2-dose COVID-19 vaccine series (with a homologous or heterologous schedule using mRNA or viral vector vaccines), an additional dose of an authorized mRNA COVID-19 vaccine should be offered (NACI, 2021).

- Addition to Anaphylaxis under contraindication row: NOTE: In individuals with a history of a severe, immediate (≤4h following vaccination) allergic reaction (e.g., anaphylaxis) after previous administration of an mRNA COVID-19 vaccine, re-vaccination (i.e. administration of a subsequent dose in the series when indicated) may be offered with the same vaccine or the same mRNA platform if a risk assessment deems that the benefits outweigh the potential risks for the individual and if informed consent is provided.
- Under possible reaction row, common side effect updated as per the most current product monograph.
- NEW recommendation:
  Second Dose for 12 Year Olds if First Dose was Pediatric Formulation
  - Give vaccine appropriate for age at time of second dose, regardless of initial dose received: e.g., for children who received the pediatric vaccine as a first dose when they were 11, complete second dose with the 12+ years formulation.

- NEW! Pfizer 5-11 years COVID-19 vaccine (Orange cap and Labe border)
  - Please review content.
  - This vaccine **cannot** be stored between -25 to -15C.
  - **PLEASE review storage and handling information as different that +12 years formulation.**
  - DOSE: 0.2 ml. NOTE: an 11 year old who previously received the +12 years formulation 0.3ml dose and is still 11 at time of second dose should receive the pediatric 0.2 ml dose to complete their series.
  - NEW Precaution for Comirnaty:
    Multi-inflammatory syndrome in children (MIS-C)
    - For children with a previous history of MIS-C, vaccination with COVID-19 vaccine should be postponed until clinical recovery has been achieved or until it has been at least 90 days since diagnosis, whichever is longer.

- Provision of COVID-19 Vaccine Booster Doses
  - Pfizer-Pfizer-Moderna and Modern-Moderna-Pfizer added to table.